127- Li J, Paulson SK, Chiu Y-L, Robinson A, Lomax KG, Pollac PF. Evaluation of potential cor-
relations between serum adalimumab concentration and remission in patients with Crohn’s
disease in classic I and II. Gastroenterology. 2010;138(5):S101; [Abstract]. - Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein
GR. Reinduction with certolizumab pegol in patients with relapsed Crohn’s disease: results
from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010;8(8):696–702.e691. - Sandborn WJ, Hanauer SB, Pierre-Louis B, Lichtenstein GR. Certolizumab pegol plasma
concentration and clinical remission in Crohn’s disease. Gastroenterology. 2012;142(5):S563;
[Abstract Su2079]. - Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure-response relationship
of golimumab in patients with moderately-to-severely active ulcerative colitis: results from
phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2016;11(1):35–46. - Scott FI, Lichtenstein GR. Advances in therapeutic drug monitoring of biologic thera-
pies in inflammatory bowel disease: 2015 in review. Curr Treat Options Gastroenterol.
2016;14(1):91–102. - Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous
mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in
patient serum. J Immunol Methods. 2012;382(1–2):177–88. - Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel
disease. Inflamm Bowel Dis. 2015;21(6):1435–42. - Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab
therapy eliminates antidrug antibodies in serum and restores clinical response of patients with
inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–7. - Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human
anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am
J Gastroenterol. 2010;105(5):1133–9. - Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on
pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71. - Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to inflix-
imab may not predict response to intensification of infliximab therapy in patients with inflam-
matory bowel disease. Inflamm Bowel Dis. 2012;18(7):1199–206. - Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associ-
ated with outcome of interventions after loss of response to infliximab or adalimumab. Clin
Gastroenterol Hepatol. 2015;13(3):522–530.e522. - Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective
than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to
infliximab. Clin Gastroenterol Hepatol. 2013;11(6):654–66. - Velayos F. Reply: to PMID 23357488. Clin Gastroenterol Hepatol. 2014;12(2):346.
- Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective
than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treat-
ment: a randomised, controlled trial. Gut. 2014;63(6):919–27. - Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz
AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for
patients with inflammatory bowel disease: results from a pilot observational study. Inflamm
Bowel Dis. 2014;20(11):1996–2003. - Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide
dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–
1329.e1323. - OP029. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients
with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns
Colitis. 2016;10(Suppl 1):S24.21–S24.
8 Therapeutic Drug Monitoring of Biologic Agents